An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome
- 407 Downloads
Endoxifen concentrations have been associated with breast cancer recurrence in tamoxifen-treated patients. However, tamoxifen itself and other metabolites also show antiestrogenic anti-tumor activity. Therefore, the aim of this study was to develop a comprehensive Antiestrogenic Activity Score (AAS), which accounts for concentration and antiestrogenic activity of tamoxifen and three metabolites. An association between the AAS and recurrence-free survival was investigated and compared to a previously published threshold for endoxifen concentrations of 5.97 ng/mL.
Patients and methods
The antiestrogenic activities of tamoxifen, (Z)-endoxifen, (Z)-4-hydroxytamoxifen, and N-desmethyltamoxifen were determined in a cell proliferation assay. The AAS was determined by calculating the sum of each metabolite concentration multiplied by an IC50 ratio, relative to tamoxifen. The AAS was calculated for 1370 patients with estrogen receptor alpha (ERα)-positive breast cancer. An association between AAS and recurrence was investigated using Cox regression and compared with the 5.97 ng/mL endoxifen threshold using concordance indices.
An AAS threshold of 1798 was associated with recurrence-free survival, hazard ratio (HR) 0.67 (95% confidence interval (CI) 0.47–0.96), bias corrected after bootstrap HR 0.69 (95% CI 0.48–0.99). The concordance indices for AAS and endoxifen did not significantly differ; however, using the AAS threshold instead of endoxifen led to different dose recommendations for 5.2% of the patients.
Endoxifen concentrations can serve as a proxy for the antiestrogenic effect of tamoxifen and metabolites. However, for the aggregate effect of tamoxifen and three metabolites, defined by an integrative algorithm, a trend towards improving treatment is seen and moreover, is significantly associated with breast cancer recurrence.
KeywordsTamoxifen Metabolites Algorithm Recurrence-free survival
This work was supported by data from the WHEL study, which was initiated with the support of the Walton Family Foundation and was continued with funding from National Cancer Institute (CA69375). SC Linn received research funding from A Sister’s Hope. L Natarajan was partially supported by funding from the National Cancer Institute R01 (CA166293). BA Parker received (institutional) research funding from Genentech, Novartis, and GlaxoSmithKline.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Gray R, Rea D, Handley K (2013) ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31: suppl; abstr 5Google Scholar
- 4.Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 12:1101–1108CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629CrossRefPubMedGoogle Scholar
- 22.Coezy E, Borgna J, Rochefort H (1982) Tamoxifen and metabolites in MCF 7 cells : correlation between binding to estrogen receptor and inhibition of cell growth tamoxifen and metabolites in MCF7 cells : correlation between binding. Cancer Res 41:317–323Google Scholar
- 27.Teunissen SF, Jager NGL, Rosing H et al (2011) Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 879:1677–1685CrossRefGoogle Scholar
- 30.R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/